Literature DB >> 8303231

Who should receive high-cost mental health treatment and for how long?

R Rosenheck1, L Massari, L Frisman.   

Abstract

The use of some recently developed and promising mental health treatments is likely to be restricted by their high cost. Cost-effectiveness studies, however, suggest that high treatment costs may be offset by associated reductions in inpatient service use. In view of the considerable variation in the cost of inpatient treatment for the mentally ill, it may be cost-efficient to use high-cost treatments for frequent hospital users but not for others. To illustrate this principle, we examine 9-year trends in inpatient costs incurred by schizophrenia patients discharged from Department of Veterans' Affairs medical centers across the country in fiscal year (FY) 1982. Even in the absence of specific intervention, average inpatient costs in this sample fell 49 percent, from $7,368 per patient in FY 1983 to $3,770 per patient in FY 1990, reducing the potential for inpatient cost offsets over time. Sensitivity analyses of potential inpatient cost offsets were conducted using a range estimate both for the cost of treatment and for resulting reductions in inpatient expense. Assuming effectiveness in a middle range, high-cost intervention was projected to be cost-neutral for the 25 percent of the sample with the highest rates of baseline hospital use for a duration of 1-3 years. Although our specific model had low predictive power, the projection of cost offsets in large mental health systems deserves further examination and may prove to be one useful criterion, in addition to clinical effectiveness, for selecting patients to receive expensive treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8303231     DOI: 10.1093/schbul/19.4.843

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  9 in total

1.  Adequacy of treatment for serious mental illness in the United States.

Authors:  Philip S Wang; Olga Demler; Ronald C Kessler
Journal:  Am J Public Health       Date:  2002-01       Impact factor: 9.308

2.  Epidemiologic assessment of overmet need in mental health care.

Authors:  E Lin; P N Goering; A Lesage; D L Streiner
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-08       Impact factor: 4.328

3.  Older adult patients with both psychiatric and substance abuse disorders: prevalence and health service use.

Authors:  H G Prigerson; R A Desai; R A Rosenheck
Journal:  Psychiatr Q       Date:  2001

Review 4.  Risperidone. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

5.  Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.

Authors:  G Ginsberg; S Shani; B Lev
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

6.  The prevalence and correlates of untreated serious mental illness.

Authors:  R C Kessler; P A Berglund; M L Bruce; J R Koch; E M Laska; P J Leaf; R W Manderscheid; R A Rosenheck; E E Walters; P S Wang
Journal:  Health Serv Res       Date:  2001-12       Impact factor: 3.402

Review 7.  Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia.

Authors:  D A Revicki
Journal:  J Psychiatry Neurosci       Date:  1997-07       Impact factor: 6.186

8.  Disparities in mental health service use of racial and ethnic minority elderly adults.

Authors:  Daniel E Jimenez; Ben Cook; Stephen J Bartels; Margarita Alegría
Journal:  J Am Geriatr Soc       Date:  2012-12-18       Impact factor: 5.562

9.  Factors explaining priority setting at community mental health centres: a quantitative analysis of referral assessments.

Authors:  Sverre Grepperud; Per Arne Holman; Knut Reidar Wangen
Journal:  BMC Health Serv Res       Date:  2014-12-14       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.